# Cost Extension for Ramon Ayon Diversity Supplement

> **NIH NIH R01** · UNIVERSITY OF VIRGINIA · 2024 · $171,494

## Abstract

This proposal focuses on our discovery of new signaling pathways mediated by the p90 ribosomal S6
kinase (RSK2) that regulate vascular smooth muscle (VSM) mediated vascular resistance, myogenic
tone and blood flow with the rational that outcomes have potential to deliver new therapeutic targets.
The myogenic response of small resistance arteries is critical for protection of downstream arterioles
and capillaries against barotrauma due to excessive changes in intravascular pressure. Our
understanding of the signaling pathways that control myogenic and agonist-mediated vasoconstriction,
vascular resistance and blood pressure homeostasis are incomplete and this proposal addresses this
gap in our knowledge base. Our overall objective is to determine the contribution of RSK2 to vascular
physiology and pathophysiology from a mechanistic and functional perspective. Our central hypothesis
is that RSK2 kinase mediates a novel network of pathways that result in regulation of VSM contraction
in response to myogenic pressure and to agonists. This hypothesis is based on preliminary data
identifying three RSK2 targets in resistance arteries which potentiate the contractile state: (1) RLC20,
leading to direct augmentation of the canonical activation of myosin cross-bridge function; (2) NHE-1
Na+ /H+ exchanger, the phosphorylation of which contributes to an increase in pHi associated with an
increase in cytosolic [Ca2+], thereby potentiating the MLCK-mediated pathway; and (3) two RhoA-
specific nucleotide exchange factors, with potential regulatory impact on the RhoA-mediated pathway.
Our preliminary data also suggest that RSK2 signaling contributes ~20% of maximal myogenic force
and that arteries from a Rsk2-/- mouse or treated with RSK inhibitors are more dilated, have reduced
myogenic tone and RLC20 phosphorylation and that Rsk2-/- mice have lower blood pressure compared
to wild-type mice. We hypothesize that this non-canonical RSK2 pathway augments and cross talks
with the canonical Ca2+/MLCK and RhoA/ROCK Ca2+-sensitization pathways to regulate
vasoconstriction and basal BP. The following aims test our hypotheses: Aim 1: To determine how RSK2
contributes to VSM contraction in response to perfusion pressure and agonists, with a focus on select
phosphorylation targets, i.e. RLC20, NHE-1 and RhoGEFs. Aim 2: To assess the contribution of RSK2
to blood pressure homeostasis. Outcomes are expected to establish and add a new RSK2 mediated
signaling network to the canonical MLCK and RhoA/ROCK signaling pathways regulating VSM tone
and vasoconstriction and to provide possible new therapeutic targets for contractile pathologies of the
vessel wall.

## Key facts

- **NIH application ID:** 10916816
- **Project number:** 3R01HL147555-04S2
- **Recipient organization:** UNIVERSITY OF VIRGINIA
- **Principal Investigator:** Zygmunt S Derewenda
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $171,494
- **Award type:** 3
- **Project period:** 2020-01-15 → 2024-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10916816

## Citation

> US National Institutes of Health, RePORTER application 10916816, Cost Extension for Ramon Ayon Diversity Supplement (3R01HL147555-04S2). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10916816. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*